- Home
- PBYI vs ANL Comparison
PBYI vs ANL Comparison
Compare PBYI & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBYI | ANL |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.9M | 406.5M |
| IPO Year | 2011 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PBYI | ANL |
|---|---|---|
| Price | $7.57 | $15.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 257.8K | ★ 350.7K |
| Earning Date | 05-07-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $27,685,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.75 | $0.88 |
| 52 Week High | $7.90 | $13.00 |
Technical Indicators
Market Signals| Indicator | PBYI | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 67.52 | 80.26 |
| Support Level | $5.75 | $1.36 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.33 | 1.38 |
| MACD | 0.14 | 0.70 |
| Stochastic Oscillator | 82.18 | 99.31 |
Price Performance
Historical ComparisonAbout PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.